CRISPR Therapeutics AG (CRSP) EBIAT (2016 - 2025)
Historic EBIAT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$130.6 million.
- CRISPR Therapeutics AG's EBIAT fell 25006.57% to -$130.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$581.6 million, marking a year-over-year decrease of 5879.75%. This contributed to the annual value of -$581.6 million for FY2025, which is 5879.75% down from last year.
- CRISPR Therapeutics AG's EBIAT amounted to -$130.6 million in Q4 2025, which was down 25006.57% from -$106.4 million recorded in Q3 2025.
- CRISPR Therapeutics AG's EBIAT's 5-year high stood at $759.2 million during Q2 2021, with a 5-year trough of -$208.5 million in Q2 2025.
- For the 5-year period, CRISPR Therapeutics AG's EBIAT averaged around -$68.7 million, with its median value being -$114.9 million (2021).
- Its EBIAT has fluctuated over the past 5 years, first skyrocketed by 105312.97% in 2021, then crashed by 25006.57% in 2025.
- CRISPR Therapeutics AG's EBIAT (Quarter) stood at -$141.2 million in 2021, then grew by 21.72% to -$110.6 million in 2022, then surged by 180.8% to $89.3 million in 2023, then crashed by 141.76% to -$37.3 million in 2024, then tumbled by 250.07% to -$130.6 million in 2025.
- Its EBIAT stands at -$130.6 million for Q4 2025, versus -$106.4 million for Q3 2025 and -$208.5 million for Q2 2025.